entospletinib entospletinib entospletinib is an experimental drug for the treatment of various types of cancer under development by gilead sciences. it is an inhibitor of spleen tyrosine kinase (syk). it has entered clinical trials for acute myeloid leukaemia (aml), chronic lymphocytic leukemia (cll), diffuse large b cell lymphoma (dlbcl), graft-versus-host disease (gvhd), hematological malignancies, mantle cell lymphoma (mcl), and non-hodgkin lymphoma (nhl). entospletinibclinical dataother namesgs-9973legal statuslegal status investigational identifiers iupac name 6-(1h-indazol-6-yl)-n-(4-morpholin-4-ylphenyl)imidazopyrazin-8-amine cas number1229208-44-9pubchem cid59473233drugbank12121unii6i3o3w6o3bkeggd11209chemical and physical dataformulac23h21n7omolar mass411.469 g·mol−13d model (jsmol)interactive image smiles c1cn2cc(-c3ccc4cnc4c3)nc(nc3ccc(n4ccocc4)cc3)c2n1 inchi inchi=1s/c23h21n7o/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15h,9-12h2,(h,25,28)(h,26,27)key:xsmsnfmdvxxhgj-uhfffaoysa-n